- Conditions
- Healthy
- Interventions
- Estradiol followed by progesterone, Raloxifene
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 329
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Eating Disorders, Hypoestrogenemia
- Interventions
- 17-β estradiol transdermal patches with cyclic progesterone, Placebo patch and pill
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 35 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-positive Breast Cancer
- Interventions
- Anastrozole, Denifanstat, Exemestane, Fulvestrant, Echocardiography, Letrozole, Paclitaxel, Trastuzumab, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy
- Drug · Procedure · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Breast Cancer Metastatic
- Interventions
- Amcenestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Bakersfield, California • Santa Monica, California + 11 more
- Conditions
- Breast Cancer, Breast Neoplasms
- Interventions
- Bevacizumab, Anastrozole, Fulvestrant
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 11
- States / cities
- Fort Myers, Florida • Jacksonville, Florida • Orlando, Florida + 8 more
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, MK-0646, Dasatinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Neoplasms, Neoplasm Metastasis
- Interventions
- Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 874 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 48
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Greenbrae, California + 29 more
- Conditions
- Determine the Effects of Nitrosigine and Citrulline-malate on Flow-mediated Dilation Among Young Adults
- Interventions
- inositol-stabilized arginine silicate
- Dietary Supplement
- Lead sponsor
- University of Arkansas, Fayetteville
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- Metastatic Pancreatic Neuroendocrine Tumor
- Interventions
- Fulvestrant, 177Lu-DOTATATE
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Contraception
- Interventions
- Relugolix Combination Therapy
- Drug
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 1,164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 109
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more
- Conditions
- Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
- Interventions
- AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab
- Drug
- Lead sponsor
- Aminex Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Prostate Cancer
- Interventions
- Estramustine, Vinorelbine
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Suppression of Ovulation
- Interventions
- 10 µg/day E2 with NES 200® µg/day, 20 µg/day E2 with NES 200® µg/day, 40 µg/day E2 with NES 200® µg/day
- Drug
- Lead sponsor
- Kimberly Myer
- Other
- Eligibility
- 18 Years to 39 Years · Female only
- Enrollment
- 197 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 8
- States / cities
- Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 4 more
- Conditions
- Solid Tumors and Lymphomas
- Interventions
- Alobresib, Exemestane, Fulvestrant
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Fort Wayne, Indiana • Goshen, Indiana + 1 more
- Conditions
- Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma
- Interventions
- Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Therapeutic Estradiol
- Procedure · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Premenstrual Syndrome
- Interventions
- Levonorgestrel/Ethinyl Estradiol
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 40 more
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, Anastrozole, Everolimus, Placebo - Anastrozole, Placebo - Everolimus
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 223
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 150 more
- Conditions
- Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
- Interventions
- AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
- Drug · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Advanced Solid Tumors
- Interventions
- SNV4818, Fulvestrant, Palbociclib
- Drug
- Lead sponsor
- Pikavation Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
- Conditions
- Malignant Neoplasms of Female Genital Organs
- Interventions
- Fulvestrant, Abemaciclib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cardiovascular Risk Factor
- Interventions
- No to Low Endogenous Estrogen, Estradiol
- Other
- Lead sponsor
- University of Delaware
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, flutamide, ketoconazole, paclitaxel, releasing hormone agonist therapy, vinblastine sulfate
- Drug
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 75
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 63 more
- Conditions
- Pelvic Floor Disorders
- Interventions
- Postmenopausal, topical vaginal estrogen cream, Placebo Comparator: Postmenopausal, topical placebo cream
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 21 Years to 70 Years · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Acne Vulgaris
- Interventions
- YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 14 Years to 45 Years · Female only
- Enrollment
- 541 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2004
- U.S. locations
- 22
- States / cities
- Mobile, Alabama • Kingman, Arizona • Encino, California + 18 more